A Phase Ia Clinical Trial of HW241045

Recruiting now · Phase 1 · Has a placebo group

Conditions studied: Healthy Volunteers, IPF

In brief

This is a Phase Ia, randomized, double-blind, placebo-controlled study to assess the safety, tolerability and pharmacokinetic (PK) of HW241045 in healthy subjects following a single ascending dose.

Key facts

Study ID

NCT07448194

Run by

Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.

People needed

56

Starts

2025-11-24

Expected to finish

2026-06-01

Last updated by the study team

2026-03-04

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

Where it is running

• Peking Union Medical College Hospital — Beijing, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.